These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16127808)

  • 1. MS drug withdrawn from market.
    FDA Consum; 2005; 39(3):3. PubMed ID: 16127808
    [No Abstract]   [Full Text] [Related]  

  • 2. Tysabri withdrawal calls entire class into question.
    Singer E
    Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500
    [No Abstract]   [Full Text] [Related]  

  • 3. MS drug back on market under restricted program.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
    [No Abstract]   [Full Text] [Related]  

  • 4. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B; Sandrock A; Panzara MA
    N Engl J Med; 2005 Jul; 353(4):432-3. PubMed ID: 15947083
    [No Abstract]   [Full Text] [Related]  

  • 5. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
    Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
    [No Abstract]   [Full Text] [Related]  

  • 7. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 8. Tysabri raises alarm bells on drug class.
    Sheridan C
    Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
    [No Abstract]   [Full Text] [Related]  

  • 9. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of multiple sclerosis].
    Holmøy T; Harbo HF; Celius EG
    Tidsskr Nor Laegeforen; 2010 May; 130(9):923; author reply 923. PubMed ID: 20453948
    [No Abstract]   [Full Text] [Related]  

  • 11. Third Tysabri adverse case hits drug class.
    Sheridan C
    Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
    [No Abstract]   [Full Text] [Related]  

  • 12. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 13. [Natalizumab in multiple sclerosis].
    Rajda C; Bencsik K; Vécsei L;
    Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
    [No Abstract]   [Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Berger T; Deisenhammer F
    N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16236749
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 16. Natalizumab: a double-edged sword?
    DeAngelis LM
    Ann Neurol; 2009 Sep; 66(3):262-3. PubMed ID: 19798644
    [No Abstract]   [Full Text] [Related]  

  • 17. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
    Achiron A; Miron S; Shoenfeld Y
    Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
    [No Abstract]   [Full Text] [Related]  

  • 18. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Ko MY; Stefoski D; Balabanov R
    Neurology; 2011 Sep; 77(10):1020; author reply 1020. PubMed ID: 21893676
    [No Abstract]   [Full Text] [Related]  

  • 19. The trials and tribulations of Tysabri.
    Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
    [No Abstract]   [Full Text] [Related]  

  • 20. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.